Breaking News

Breaking News English

Urgent::www.AMUNetwork.com needs Part Time campus Reporters.Please Contact:-deskamunetwork@gmail.com
Prof. Tariq Mansoor is presently serving as the Vice-Chancellor, Aligarh Muslim University, Aligarh. Previously he has also served as Principal, J.N. Medical College, Chief Medical Superintendent, J.N. Medical College Hospital and Chairman, Department of Surgery. He is also the member of Medical Council of India since March 2015 for a period of four years. He is product of the first batch of prestigious Our Lady of Fatima Higher Secondary School, Aligarh. During his school days he has served as House Captain as well as School Captain. He did his MBBS and MS in General Surgery from Jawaharlal Nehru Medical College, AMU, Aligarh. A surgeon by profession with special interest in Breast and Thyroid Diseases, Prof. Tariq Mansoor has 33 years of Teaching and 35 years of Clinical experience. He has 90 publications to his credit and has guided 49 Postgraduate Medical Students for their Thesis as Supervisor / Co-Supervisor

A potential new weapon against heart failure

A potential new weapon against heart failure

Washington : A team of researchers has come up with a way to prevent heart failure.

Researchers at the Cincinnati Children’s Heart Institute used an experimental targeted molecular therapy to block a matrix-forming protein in heart cells damaged by heart attack, reducing levels of scarred muscle tissue and saving mouse models from heart failure.

The team tested a manufactured peptide called pUR4 to block the fibronectin protein in human heart cells donated by heart failure patients.

The treatment helped human heart cells from failing and also restored their function. It also reduced fibrosis and improved heart function after a simulated heart attack in mice.

“Our data are a strong proof of principle and the first to show that inhibiting fibronectin polymerization preserves heart function, reduces left ventricle remodeling and limits formation of fibrotic connective tissue,” said lead investigator Burns Blaxall.

The researchers emphasised that it was too early to know whether the experimental therapy in this study could one day be used to treat human heart patients clinically.

The study appears in the journal Circulation.(ANI)

Read More

from The Siasat Daily

No comments:

Post a Comment